MINOCYCLINE HYDROCHLORIDE (minocycline hydrochloride) by Fosun Pharma is clinical pharmacology following a single dose of two minocycline hydrochloride capsules, 100 mg administered to 18 normal fasting adult volunteers, maximum serum concentrations were attained in 1 to 4 hours (average 2. First approved in 1982.
Drug data last refreshed 5d ago
Minocycline hydrochloride is an oral tetracycline antibiotic indicated for rosacea, a chronic inflammatory skin condition. It works by inhibiting bacterial protein synthesis and has activity against gram-positive and gram-negative organisms, with a half-life of 11-22 hours in normal volunteers. The drug achieves peak serum concentrations in 1-4 hours and may be taken with or without food.
As a 40+ year-old drug approaching loss of exclusivity with moderate competitive pressure (30%), the brand team is likely consolidating support and transitioning to defensive positioning rather than growth initiatives.
CLINICAL PHARMACOLOGY Following a single dose of two minocycline hydrochloride capsules, 100 mg administered to 18 normal fasting adult volunteers, maximum serum concentrations were attained in 1 to 4 hours (average 2.1 hours) and ranged from 2.1 to 5.1 mcg/mL (average 3.5 mcg/mL). The serum…
Worked on MINOCYCLINE HYDROCHLORIDE at Fosun Pharma? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Minocycline Hydrochloride in Reducing Chemotherapy-Induced Peripheral Neuropathy and Acute Pain in Patients With Breast Cancer Undergoing Treatment With Paclitaxel
Working on minocycline hydrochloride offers limited career growth as a mature, post-LOE product with zero linked job openings and facing intense competitive pressure. Roles available are primarily defensive—managing existing accounts, navigating generic competition, and capturing remaining market share in a crowded dermatology landscape.